Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
,
These cookies are for your convenience so that you do not need to re-enter your details when leaving another comment
Phase 3 Development and Current Evidence Level Retatrutide is in phase 3 development for several metabolic indications, including obesity and type 2 diabetes, while published phase 2 trials and 2026 phase 3 reports provide the main current human evidence [2], [7], [8]
306 , E1248E1256 (2014)
Luo J, Feldman R, Korytkowski M, et al
The research team found that participants with genetic makeup mimicking the effect of GLP-1 receptor agonists leads to reductions in both lean mass (whole-body fat-free mass and trunk fat-free mass) and body fat (whole-body fat mass, trunk fat percentage and body fat percentage)
US$ 24.01
US$ 27.31
US$ 22.02
US$ 28.25
US$ 29.35
US$ 23.67
US$ 24.96
